Latest Breaking News On - Vince angotti - Page 1 : vimarsana.com

Talphera, Inc (NASDAQ:TLPH) Q1 2024 Earnings Call Transcript

Talphera, Inc (NASDAQ:TLPH) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Raffi asadorianShakil aslamJames molloyVince angottiPam palmerEd arceClinical developmentExchange commissionTeliphone corpAlliance global partnersTalphera incBiocryst pharmaceuticalsGeorgetown universityCall transcript mayTalphera first quarterResults conference

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAbhinav jainVince angottiTalphera incPrnewswire talphera incDepartment of defenseExchange commissionNantahala capitalRosalind advisorsNantahala capital managementTalphera boardTalphera chief executiveBreakthrough designationPivotal trial milestoneSecurities actBreakthrough device designation

AcelRx Announces Rebranding With Name Change to Talphera, Inc

Name change to Talphera reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq.

Vince angottiTalphera incExchange commissionPrnewswire acelrx pharmaceuticals incPremarket approvalNasdaq global marketChief executive officerNafamostat efficacyInstitutional review boardBreakthrough device designationBreakthrough device designation statusPrivate securities litigation reform act

AcelRx Pharmaceuticals, Inc (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript

Operator: Welcome to the AcelRx third quarter 2023 financial results conference call.

South koreaVince angottiThomas yipLaurence busseDavid boldtPam palmerJames molloyRaffi asadorianEd arceEmory university school of medicineExchange commissionUniversity of pittsburgh medical centerDepartment of defense or doDepartment of defenseAcelrx pharmaceuticals incAlliance global partners

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter.

United statesVince angottiDepartment of defenseCompany annual report on formDrug administrationExchange commissionPrnewswire acelrx pharmaceuticals incNasdaq stock marketAcelrx pharmaceuticals incInvestigational device exemptionOpinion leaderChief executive officerNafamostat efficacyPremarket approvalKey opinion leaderInstitutional review board